---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007002"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:41:10.806695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma FY2022 cash $69.3M; Phase 3 EFZO-FIT enrolling globally; $52M Feb offering extends runway to 2026

## Summary
- Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.
- R&D expense $42.8M, G&A $14.0M for full year 2022; pre-revenue biotech with no product sales.
- Phase 3 EFZO-FIT (sarcoidosis) enrolling in U.S., Europe, Japan; Kyorin dosed first patient in Japan triggering $10M milestone.
- FDA cleared IND for Phase 2 proof-of-concept SSc-ILD study; EU orphan designation for efzofitimod in sarcoidosis.
- LTBP1 identified as target of DARS domain; European patent allowance for efzofitimod + pirfenidone combo.

## SEC filing metadata
- accession: 0000950170-23-007002
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/0000950170-23-007002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/life-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007002
- JSON: https://secwatch.observer/filing/0000950170-23-007002.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007002.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for year ended December 31, 2022.
  - Period: year ended December 31, 2022
  - Result: reported results
  source text: On March 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/0000950170-23-007002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.